» Articles » PMID: 28119425

Outcomes From a Hearing-Targeted Cytomegalovirus Screening Program

Overview
Journal Pediatrics
Specialty Pediatrics
Date 2017 Jan 26
PMID 28119425
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Cytomegalovirus (CMV) is the most common congenital infection and nongenetic cause of congenital sensorineural hearing loss in the United States. Utah was the first state to pass legislation mandating CMV screening for newborns who fail newborn hearing screening (NBHS). The study objective was to present outcomes of hearing-targeted CMV screening and determine factors predicting CMV screening.

Methods: We used Utah Department of Health HiTrack and Vital Records databases to examine CMV screening from 509 infants who failed NBHS in the 24 months after implementation of the Utah legislation. Multivariate logistic regression analyses were conducted to identify predictors of compliance with CMV screening and diagnostic hearing evaluation.

Results: Sixty-two percent of infants who never passed hearing screening underwent CMV screening. Fourteen of 234 infants tested within 21 days were CMV positive; 6 (42.9%) had hearing loss. Seventy-seven percent of eligible infants completed a diagnostic hearing evaluation within 90 days of birth. Compliance with CMV screening was associated with sociodemographic factors, time since the law was enacted, and NBHS protocol. Infants born after the legislation showed greater odds of achieving timely diagnostic hearing evaluation than infants born before the law.

Conclusions: Incorporating CMV screening into an established NBHS program is a viable option for the identification of CMV in infants failing NBHS. The addition of CMV testing can help a NBHS program attain timely audiological diagnostics within 90 days, an important early hearing detection and intervention milestone.

Citing Articles

Congenital cytomegalovirus screening in neonates born after 35 weeks gestation-is targeted screening beneficial?.

Aldon M, Raveentheran G, Amin Z, Chan S, Aoyama R, Tee N Front Pediatr. 2025; 13:1510612.

PMID: 40017708 PMC: 11865022. DOI: 10.3389/fped.2025.1510612.


Timing of congenital cytomegalovirus diagnosis and missed opportunities.

Baker M, Wang X, Melvin A Front Pediatr. 2025; 13:1475121.

PMID: 39967745 PMC: 11832646. DOI: 10.3389/fped.2025.1475121.


American Cochlear Implant Alliance Position Statement on Newborn Congenital Cytomegalovirus Screening.

Pesch M, Brown K, Birath A, Demmler-Harrison G, Sapp C, Selleck A Otolaryngol Head Neck Surg. 2024; 172(2):728-733.

PMID: 39666828 PMC: 11773442. DOI: 10.1002/ohn.1079.


Beyond Awareness: Hope for a CMV Vaccine! An Introduction to the Conference, "CMV Vaccine Development-How Close Are We?" (27-28 September 2023).

Pesch M, Schleiss M, Plotkin S, Permar S, Gautam R Vaccines (Basel). 2024; 12(11).

PMID: 39591129 PMC: 11598857. DOI: 10.3390/vaccines12111226.


Burden of Congenital CMV Infection: A Narrative Review and Implications for Public Health Interventions.

Liberati C, Sturniolo G, Brigadoi G, Cavinato S, Visentin S, Cosmi E Viruses. 2024; 16(8).

PMID: 39205285 PMC: 11360585. DOI: 10.3390/v16081311.